Histogenics (HSGX) and Pfizer (PFE) Head to Head Analysis

Pfizer (NYSE: PFE) and Histogenics (NASDAQ:HSGX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Pfizer and Histogenics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pfizer $52.55 billion 3.96 $21.31 billion $3.52 9.93
Histogenics N/A N/A -$16.20 million ($0.22) -11.86

Pfizer has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Dividends

Pfizer pays an annual dividend of $1.36 per share and has a dividend yield of 3.9%. Histogenics does not pay a dividend. Pfizer pays out 38.6% of its earnings in the form of a dividend. Histogenics has raised its dividend for 8 consecutive years.

Insider & Institutional Ownership

70.1% of Pfizer shares are held by institutional investors. Comparatively, 44.1% of Histogenics shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 23.8% of Histogenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Pfizer and Histogenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pfizer 40.55% 26.86% 9.44%
Histogenics N/A -658.91% -106.38%

Analyst Recommendations

This is a summary of recent recommendations for Pfizer and Histogenics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer 1 9 8 0 2.39
Histogenics 0 0 2 0 3.00

Pfizer presently has a consensus target price of $39.29, suggesting a potential upside of 12.46%. Histogenics has a consensus target price of $4.00, suggesting a potential upside of 53.26%. Given Histogenics’ stronger consensus rating and higher probable upside, analysts plainly believe Histogenics is more favorable than Pfizer.

Risk & Volatility

Pfizer has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Histogenics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.

Summary

Pfizer beats Histogenics on 10 of the 16 factors compared between the two stocks.

Pfizer Company Profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Histogenics Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply